Indications and strategies for continuing GH treatment during transition from late adolescence to early adulthood in patients with GH deficiency: the impact on bone mass.
GH plays an important role in longitudinal bone growth and maturation during childhood and adolescence. However, GH has important metabolic functions other than bone growth, which become more apparent during young adulthood, when growth has been completed. Indeed, GH deficiency (GHD) in adult life is a recognized clinical syndrome which includes symptoms such as increased central adiposity, decreased lean body mass, reduced bone mineral density (BMD), increased atherogenic risk, cerebrovascular and cardiac morbidity and mortality, and reduced quality of life. As approximately one quarter of the children with GHD should continue GH administration in adulthood, it is important to reconfirm GHD at the end of growth in order to select patients with severe GHD who need to resume GH therapy with an appropriate age-related dosage. Some evidence indicates that most peak bone mass (PBM) is achieved by the end of adolescence but small increases in BMD continue during the period of transition from late adolescence to young adulthood. Some young adults with GHD show a persistent increase of lumbar BMD after the completion of growth even after discontinuation of treatment suggesting a spontaneous progression towards lumbar PBM or a continuing effect of the treatment. The data indicates that adolescents with GHD who do not reach lumbar PBM at the time of discontinuation of GH treatment can achieve a BMD lower than their genetic potential if they are not treated during the transition to young adulthood.
Saggese
G
G
Department of Reproductive Medicine and Pediatrics, University of Pisa, Pisa, Italy. g.saggese@med.unipi.it
Baroncelli
G I
GI
Vanacore
T
T
Fiore
L
L
Ruggieri
S
S
Federico
G
G
D000293:Adolescent; D000328:Adult; D001827:Body Height; D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects*; D001846:Bone Development; D005260:Female; D019382:Human Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use*; D006801:Humans; D008159:Lumbar Vertebrae; D008297:Male; D010349:Patient Compliance; D011788:Quality of Life; D014652:Vascular Diseases / Q000209:etiology / Q000517:prevention & control
D019382:Human Growth Hormone
J Clin Endocrinol Metab. 2002 Oct;87(10):4427-8
12364411
Osteoporos Int. 1997;7(6):525-32
9604047
Horm Res. 2002;58 Suppl 1:52-6
12373015
J Bone Miner Res. 1994 Aug;9(8):1319-26
7976513
J Clin Endocrinol Metab. 2000 Mar;85(3):970-6
10720025
J Bone Miner Res. 2001 Feb;16(2):398-405
11204440
Growth Horm IGF Res. 1999 Oct;9(5):290-5
10543936
J Clin Endocrinol Metab. 1996 Aug;81(8):3077-83
8768878
J Clin Endocrinol Metab. 1995 Oct;80(10):3097-8
7559905
J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1337-42
11202206
Osteoporos Int. 1997;7(4):390-406
9373575
J Clin Endocrinol Metab. 2000 Nov;85(11):3990-3
11095419
Growth Horm IGF Res. 1998 Apr;8 Suppl B:177-84
10990158
Clin Endocrinol (Oxf). 2002 Aug;57(2):273-81
12153608
J Clin Endocrinol Metab. 1997 Feb;82(2):352-6
9024217
J Clin Endocrinol Metab. 2000 Oct;85(10):3653-60
11061518
Arch Dis Child. 1987 Mar;62(3):222-6
3566314
Clin Endocrinol (Oxf). 2004 Feb;60(2):175-84
14725678
J Pediatr Endocrinol Metab. 2002 Jun;15(6):809-16
12099391
J Clin Endocrinol Metab. 1997 Aug;82(8):2423-8
9253311
J Appl Physiol Respir Environ Exerc Physiol. 1979 Mar;46(3):451-6
438011
Arch Pediatr. 1997;4(2 Suppl 2):95s-101s
9246313
Horm Res. 2002;58(5):207-14
12401939
Clin Endocrinol (Oxf). 1994 Oct;41(4):511-6
7955461
J Clin Endocrinol Metab. 1985 Mar;60(3):513-6
3972964
J Clin Endocrinol Metab. 2000 Oct;85(10):3693-9
11061526
J Pediatr. 1980 Mar;96(3 Pt 1):393-6
7359231
Drugs. 2002;62(16):2399-412
12396230
J Clin Endocrinol Metab. 1992 Oct;75(4):1060-5
1400871
J Pediatr. 1993 Jan;122(1):37-45
8419613
J Clin Endocrinol Metab. 2002 Aug;87(8):3624-31
12161486
Horm Res. 1997;48 Suppl 5:72-7
9434048
Clin Endocrinol (Oxf). 2001 Nov;55(5):617-24
11894973
J Clin Endocrinol Metab. 1998 Sep;83(9):3150-4
9745418
J Clin Invest. 1994 Feb;93(2):799-808
8113412
Pediatrics. 1999 Oct;104(4 Pt 2):1004-10
10506252
J Clin Endocrinol Metab. 1998 Feb;83(2):382-95
9467546
Horm Res. 1998;50(6):320-40
9973672
J Clin Endocrinol Metab. 1999 Apr;84(4):1324-8
10199773
J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1327-36
11202205
Endocr Rev. 1998 Feb;19(1):55-79
9494780
J Clin Endocrinol Metab. 2001 Apr;86(4):1574-9
11297586
Clin Endocrinol (Oxf). 1996 Mar;44(3):311-6
8729528
Clin Endocrinol (Oxf). 1995 Jan;42(1):3-7
7889628
Arch Dis Child. 1992 Dec;67(12):1472-4
1489227
J Bone Miner Res. 1994 Sep;9(9):1451-8
7817830
J Pediatr Endocrinol Metab. 2002 Dec;15 Suppl 5:1361-5
12510992
Horm Res. 2000;54 Suppl 1:44-51
11146379
J Clin Endocrinol Metab. 1992 Jan;74(1):118-23
1727808
Acta Paediatr Suppl. 1994 Apr;399:3-7; discussion 8
7949614
J Clin Endocrinol Metab. 1999 Jun;84(6):1919-24
10372687
Eur J Endocrinol. 2000 Apr;142(4):347-52
10754475
Clin Endocrinol (Oxf). 1996 Nov;45(5):553-6
8977751
J Clin Endocrinol Metab. 2003 Apr;88(4):1658-63
12679453
J Clin Endocrinol Metab. 1996 Mar;81(3):1248-53
8772607
Clin Endocrinol (Oxf). 2000 Nov;53(5):545-7
11106913
J Clin Endocrinol Metab. 2002 Jan;87(1):90-8
11788629
J Clin Endocrinol Metab. 1996 Apr;81(4):1586-90
8636372
J Clin Endocrinol Metab. 1991 Sep;73(3):555-63
1874933
Endocr Rev. 2001 Aug;22(4):425-50
11493578
J Pediatr Endocrinol Metab. 2000;13 Suppl 6:1343-8
11202207
Eur J Endocrinol. 1997 Sep;137(3):240-5
9330587
J Clin Endocrinol Metab. 2001 Oct;86(10):4765-70
11600538
Scand J Rehabil Med. 1989;21(1):45-53
2711137
J Clin Invest. 1999 Sep;104(6):671-2
10491399
J Clin Endocrinol Metab. 1998 Nov;83(11):3913-9
9814468
Lancet. 1994 Apr 30;343(8905):1064-8
7512681
Clin Endocrinol (Oxf). 1991 Jun;34(6):469-75
1889131
J Clin Endocrinol Metab. 2000 Nov;85(11):4173-81
11095450
Eur J Endocrinol. 2000 Jun;142(6):549-56
10822216
J Pediatr. 1991 Sep;119(3):483-5
1880667